Finally, anti-PD-L1, in conjunction with either the FGFR4 inhibitor BLU-554 or the MAPK inhibitor trametinib, significantly reduced the spread of HCC produced by the FGF19-ETV4 signaling pathway. Here, FGF19 is linked to hepatocellular carcinoma.